-
Abstract Number: 1365
Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
-
Abstract Number: 1366
Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
-
Abstract Number: 1367
Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
-
Abstract Number: 1368
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
-
Abstract Number: 1369
Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
-
Abstract Number: 1370
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
-
Abstract Number: 1371
DMARD Utilization Pattern in Older Adults with Rheumatoid Arthritis
-
Abstract Number: 1372
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
-
Abstract Number: 1373
The Effect of Methotrexate on Lipid and Apolipoprotein Levels in RA Goes Hand-in-hand with EULAR Response
-
Abstract Number: 1374
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
-
Abstract Number: 1375
Effects of Training with Blood Flow Restriction on Muscle Strength in Women with Rheumatoid Arthritis: A Randomized Clinical Trial
-
Abstract Number: 1376
Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010
-
Abstract Number: 1377
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
-
Abstract Number: 1378
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
-
Abstract Number: 1379
Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis
- « Previous Page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- …
- 181
- Next Page »